PE20120032A1 - Composicion farmaceutica oral de un derivado de n-[4-(8-bromo-7-metoxiquinolin-2-il)-1,3-tiazol-2-il]-2-metilpropanamida - Google Patents
Composicion farmaceutica oral de un derivado de n-[4-(8-bromo-7-metoxiquinolin-2-il)-1,3-tiazol-2-il]-2-metilpropanamidaInfo
- Publication number
- PE20120032A1 PE20120032A1 PE2011001059A PE2011001059A PE20120032A1 PE 20120032 A1 PE20120032 A1 PE 20120032A1 PE 2011001059 A PE2011001059 A PE 2011001059A PE 2011001059 A PE2011001059 A PE 2011001059A PE 20120032 A1 PE20120032 A1 PE 20120032A1
- Authority
- PE
- Peru
- Prior art keywords
- oil
- pharmaceutical composition
- weight
- sterfat
- total composition
- Prior art date
Links
- 239000008203 oral pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 abstract 2
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 abstract 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 abstract 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 abstract 1
- 229920002675 Polyoxyl Polymers 0.000 abstract 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940113088 dimethylacetamide Drugs 0.000 abstract 1
- 239000001087 glyceryl triacetate Substances 0.000 abstract 1
- 235000013773 glyceryl triacetate Nutrition 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 229960002622 triacetin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: (A) UN COMPUESTO DE FORMULA (1) EN UNA CANTIDAD DE 1-40% DE PESO DE LA COMPOSICION TOTAL; (B) UN TENSOACTIVO QUE TIENE UN EQUILIBRIO HIDROFILO/LIPOFILO MAYOR QUE 10 TAL COMO VITAMINA E TPGS, ACEITE DE RICINO POLIETOXILADO, ACEITE DE RICINO HIDROGENADO DE POLIOXILO, ESTER GRASO DE POLIOXIETILEN-SORBITAN, MACROGOLGLICERIDO DE CAPRILOCAPROILO O SUS MEZCLAS EN CANTIDAD DE 2-50% EN PESO DE LA COMPOSICION TOTAL (C) AL MENOS UN DISOLVENTE QUE COMPRENDA DE 10-90% EN PESO DE LA COMPOSICION TOTAL TAL COMO PROPILENGLICOL, POLIPROPILENGLICOL, POLIETILENGLICOL CON PESO MOLECULAR MAYOR QUE 300 Y MENOR QUE 600 , GLICEROL, ETANOL, TRIACETIN, DIMETIL ISOSORBIDA, GLICOFUROL, CARBONATO DE PROPILENO, AGUA, DIMETIL-ACETAMIDA O SUS MEZCLAS. DICHA COMPOSICION FARMACEUTICA NO CONTIENE LIPIDOS. LA COMPOSICION FARMACEUTICA SE ENCUENTRA EN FORMA LIQUIDA FACILITANDO SU ADMINISTRACION EN FORMA ORAL SIENDO UN INHIBIDOR VIRAL DE LA HEPATITIS C
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11678908P | 2008-11-21 | 2008-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120032A1 true PE20120032A1 (es) | 2012-02-12 |
Family
ID=41650279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001059A PE20120032A1 (es) | 2008-11-21 | 2009-11-18 | Composicion farmaceutica oral de un derivado de n-[4-(8-bromo-7-metoxiquinolin-2-il)-1,3-tiazol-2-il]-2-metilpropanamida |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US20120101049A1 (es) |
| EP (1) | EP2358355B1 (es) |
| JP (1) | JP5553839B2 (es) |
| KR (1) | KR20110087297A (es) |
| CN (1) | CN102223875A (es) |
| AR (1) | AR074391A1 (es) |
| AU (1) | AU2009316755B2 (es) |
| BR (1) | BRPI0921070A2 (es) |
| CA (1) | CA2738732A1 (es) |
| CL (1) | CL2011000878A1 (es) |
| CO (1) | CO6361900A2 (es) |
| CY (1) | CY1114892T1 (es) |
| DK (1) | DK2358355T3 (es) |
| EA (1) | EA022272B1 (es) |
| EC (1) | ECSP11011065A (es) |
| ES (1) | ES2445516T3 (es) |
| HR (1) | HRP20140097T1 (es) |
| IL (1) | IL211832A (es) |
| MA (1) | MA32812B1 (es) |
| ME (1) | ME01614B (es) |
| MX (1) | MX2011005151A (es) |
| MY (1) | MY155402A (es) |
| NZ (1) | NZ592383A (es) |
| PE (1) | PE20120032A1 (es) |
| PL (1) | PL2358355T3 (es) |
| PT (1) | PT2358355E (es) |
| RS (1) | RS53121B (es) |
| SG (1) | SG171771A1 (es) |
| SI (1) | SI2358355T1 (es) |
| TN (1) | TN2011000258A1 (es) |
| TW (1) | TWI469801B (es) |
| UA (1) | UA105777C2 (es) |
| UY (1) | UY32252A (es) |
| WO (1) | WO2010059667A1 (es) |
| ZA (1) | ZA201102029B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| KR101685941B1 (ko) * | 2009-07-07 | 2016-12-13 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃ형 간염 바이러스 프로테아제 억제제를 위한 약제학적 조성물 |
| CN103228278A (zh) | 2010-09-30 | 2013-07-31 | 贝林格尔.英格海姆国际有限公司 | 治疗hcv感染的组合疗法 |
| CA2811799A1 (en) * | 2010-10-08 | 2012-04-12 | Novartis Ag | Vitamin e formulations of sulfamide ns3 inhibitors |
| CA2822556A1 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
| PE20140039A1 (es) | 2010-12-30 | 2014-03-01 | Enanta Pharm Inc | Inhibidores de serina proteasa de hepatitis c a base de macrociclicos de fenantridina |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| SG2014011670A (en) | 2011-10-21 | 2014-10-30 | Abbvie Inc | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| SG2014011647A (en) | 2011-10-21 | 2014-08-28 | Abbvie Inc | Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon. |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| KR20140109433A (ko) * | 2012-01-12 | 2014-09-15 | 베링거 인겔하임 인터내셔날 게엠베하 | 강력한 hcv 억제제의 안정화된 약제학적 제형 |
| WO2013137869A1 (en) | 2012-03-14 | 2013-09-19 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
| WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
| JP2015512900A (ja) | 2012-03-28 | 2015-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法 |
| JP2015516421A (ja) * | 2012-05-07 | 2015-06-11 | ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ | １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの経口固形製剤 |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| US9617310B2 (en) | 2013-03-15 | 2017-04-11 | Gilead Sciences, Inc. | Inhibitors of hepatitis C virus |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| WO2017062840A1 (en) * | 2015-10-09 | 2017-04-13 | Trek Therapeutics, Pbc | Combination therapy for the treatment of hepatitis c virus |
| JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| GB0008785D0 (en) * | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| US6710195B2 (en) * | 2001-11-26 | 2004-03-23 | Supergen, Inc. | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions |
| CZ294371B6 (cs) * | 2002-06-10 | 2004-12-15 | Pliva - Lachema, A. S. | Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy |
| CL2004001161A1 (es) * | 2003-05-21 | 2005-04-08 | Boehringer Ingelheim Int | Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c. |
| JP5156374B2 (ja) * | 2004-05-25 | 2013-03-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 非環式ｈｃｖプロテアーゼインヒビターの調製方法 |
-
2009
- 2009-11-18 ME MEP-2013-140A patent/ME01614B/me unknown
- 2009-11-18 EP EP09760395.5A patent/EP2358355B1/en active Active
- 2009-11-18 PE PE2011001059A patent/PE20120032A1/es not_active Application Discontinuation
- 2009-11-18 AU AU2009316755A patent/AU2009316755B2/en not_active Expired - Fee Related
- 2009-11-18 BR BRPI0921070A patent/BRPI0921070A2/pt not_active IP Right Cessation
- 2009-11-18 CN CN2009801464655A patent/CN102223875A/zh active Pending
- 2009-11-18 MX MX2011005151A patent/MX2011005151A/es active IP Right Grant
- 2009-11-18 SI SI200930810T patent/SI2358355T1/sl unknown
- 2009-11-18 KR KR1020117011446A patent/KR20110087297A/ko not_active Withdrawn
- 2009-11-18 DK DK09760395.5T patent/DK2358355T3/da active
- 2009-11-18 JP JP2011537562A patent/JP5553839B2/ja not_active Expired - Fee Related
- 2009-11-18 WO PCT/US2009/064908 patent/WO2010059667A1/en not_active Ceased
- 2009-11-18 EA EA201100795A patent/EA022272B1/ru not_active IP Right Cessation
- 2009-11-18 US US13/129,641 patent/US20120101049A1/en not_active Abandoned
- 2009-11-18 HR HRP20140097AT patent/HRP20140097T1/hr unknown
- 2009-11-18 ES ES09760395.5T patent/ES2445516T3/es active Active
- 2009-11-18 SG SG2011036498A patent/SG171771A1/en unknown
- 2009-11-18 CA CA2738732A patent/CA2738732A1/en not_active Abandoned
- 2009-11-18 RS RS20130583A patent/RS53121B/sr unknown
- 2009-11-18 PL PL09760395T patent/PL2358355T3/pl unknown
- 2009-11-18 MY MYPI2011002269A patent/MY155402A/en unknown
- 2009-11-18 NZ NZ592383A patent/NZ592383A/xx not_active IP Right Cessation
- 2009-11-18 UA UAA201107610A patent/UA105777C2/uk unknown
- 2009-11-18 PT PT97603955T patent/PT2358355E/pt unknown
- 2009-11-20 AR ARP090104496A patent/AR074391A1/es unknown
- 2009-11-20 TW TW98139549A patent/TWI469801B/zh not_active IP Right Cessation
- 2009-11-20 UY UY0001032252A patent/UY32252A/es not_active Application Discontinuation
-
2011
- 2011-03-17 ZA ZA2011/02029A patent/ZA201102029B/en unknown
- 2011-03-21 IL IL211832A patent/IL211832A/en not_active IP Right Cessation
- 2011-04-19 CL CL2011000878A patent/CL2011000878A1/es unknown
- 2011-05-20 TN TN2011000258A patent/TN2011000258A1/fr unknown
- 2011-05-20 MA MA33867A patent/MA32812B1/fr unknown
- 2011-05-20 EC EC2011011065A patent/ECSP11011065A/es unknown
- 2011-05-24 CO CO11063891A patent/CO6361900A2/es not_active Application Discontinuation
-
2014
- 2014-01-24 CY CY20141100063T patent/CY1114892T1/el unknown
- 2014-10-17 US US14/517,242 patent/US20150038532A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120032A1 (es) | Composicion farmaceutica oral de un derivado de n-[4-(8-bromo-7-metoxiquinolin-2-il)-1,3-tiazol-2-il]-2-metilpropanamida | |
| CO6341565A2 (es) | Inhibidores macrociclicos de serina proteasas de hepatitis c | |
| CR9587A (es) | Derivados de piridazina | |
| PA8783601A1 (es) | Derivados de piperidina/piperazina | |
| TW200626558A (en) | Indazolone derivatives | |
| AR061134A1 (es) | Derivados de tioxantina | |
| ECSP055774A (es) | Nuevo medicamento para el tratamiento de la enfermedad pulmonar obstructiva crónica | |
| CU20080235A7 (es) | Composiciones farmacéuticas estabilizadas que comprenden fesoterodina | |
| MX356957B (es) | Analogos del glucagon. | |
| CO6351785A2 (es) | Inhibidores de cinasa map p39 | |
| PE20160605A1 (es) | Formulaciones de inhibidores de la syk | |
| AR088382A1 (es) | Formulaciones de etanercept estabilizadas con xilitol | |
| ECSP10010167A (es) | Composiciones oftálmicas novedosas | |
| PA8783401A1 (es) | Derivados de piperidina/piperazina | |
| ECSP11011555A (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas | |
| AR077338A1 (es) | Formulacion farmaceutica. procedimiento de preparacion. disolucion para perfusion. | |
| ECSP088229A (es) | Derivados de pirazolona como inhibidores de 11-beta hsd1 | |
| DOP2012000050A (es) | Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina | |
| SV2010003723A (es) | Derivados de piperidina 3,4-sustituida como inhibidores de renina | |
| AR063027A1 (es) | Derivados de sulfonamida | |
| CO6501175A2 (es) | Derivados de benzotiazinas, su preparación y aplicación como fármacos | |
| WO2010105951A3 (en) | Composition comprising the combination of madecassoside, of an arginine and of polysorbate | |
| UY29169A1 (es) | Derivados de 2-amido-4 feniltiazol, su preparacion y su aplicacion en terapeutica | |
| UY32299A (es) | Composiciones farmacéuticas líquidas | |
| MX338801B (es) | Composiciones de cuidado oral. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |